Afatinib is a tyrosine kinase inhibitor for managing non–small cell lung carcinoma (NSCLC). Afatinib is designed to cause irreversible inhibition of the ErbB family of tyrosine kinases. The FDA has approved afatinib for treating locally advanced or metastatic NSCLC characterized by nonresistant epidermal growth factor receptor (EGFR) mutations. Additionally, it is a second-line option for advanced squamous NSCLC. Beyond these applications, afatinib is being investigated as a monotherapy for individuals with HER2-positive breast cancer who have experienced progression despite management with trastuzumab. This activity aims to familiarize healthcare providers with afatinib’s approved indications and mechanism of action while addressing potential adverse reactions and highlighting considerations regarding toxicity.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/920
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP)
ABOHNS - 1.0 Point; Credit Type(s): Self-Assessment (ABOHNS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Adolescent Medicine, Allergy, Ambulatory/Outpatient, Chemical Pathology, Complex General Surgical Oncology, General Surgery, Hematology, Hospice & Palliative Medicine, Hospice and Palliative Medicine, Hospital Medicine, Medical Oncology, Medical Toxicology, Pediatric Critical Care Medicine, Pediatric Emergency Medicine, Pediatric Pulmonology, Pulmonary Disease, Pulmonary, Mediastinum